The company has reported total revenues of $519.97 million for the first quarter of 2009 compared to $443.22 million for the first quarter of 2008.
Frank Baldino Jr, chairman and CEO of Cephalon, said: “While the economy and various healthcare reform proposals create uncertainty for investors, we are taking steps to continue to build a world class biopharmaceutical company.
“In the short run, Amrix and Treanda will supply growth. Longer term, we expect that our recent business development transactions will enable us to create a new franchise in inflammatory diseases and our clinical development work with Nuvigil will allow it to reach new markets.”